CR20200061A - Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl) - Google Patents
Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl)Info
- Publication number
- CR20200061A CR20200061A CR20200061A CR20200061A CR20200061A CR 20200061 A CR20200061 A CR 20200061A CR 20200061 A CR20200061 A CR 20200061A CR 20200061 A CR20200061 A CR 20200061A CR 20200061 A CR20200061 A CR 20200061A
- Authority
- CR
- Costa Rica
- Prior art keywords
- dlbcl
- patient
- dlbcl patient
- novel
- obinutuzumab
- Prior art date
Links
- 229960003347 obinutuzumab Drugs 0.000 title abstract 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 13
- 238000000034 method Methods 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a obinutuzumab (o sus equivalentes funcionales) para el uso en el tratamiento de un paciente con DLBCL definido por biomarcador particular y un subgrupo de pacientes DLBCL novedoso, respectivamente. La presente invención se refiere además a un método para tratar DLBCL con obinutuzumab (o sus equivalentes funcionales) en un paciente en necesidad del mismo, en donde el paciente es un paciente con DLBCL definido por biomarcador particular o que pertenece a un subgrupo de pacientes DLBCL definido por biomarcador novedoso. La presente invención se refiere además al uso de obinutuzumab (o sus equivalentes funcionales) para la preparación de una composición farmacéutica para el tratamiento de DLBCL en el subgrupo de pacientes con DLBCL definido por biomarcador particular/paciente con DLBCL novedoso. La presente invención se refiere además a un método para identificar un subgrupo de pacientes con DLBCL particular/paciente con DLBCL novedoso y un método para diagnosticar una forma novedosa de DLBCL y un subgrupo de pacientes con DLBCL particular/paciente con DLBCL novedosos, respectivamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542489P | 2017-08-08 | 2017-08-08 | |
| PCT/EP2018/071462 WO2019030260A1 (en) | 2017-08-08 | 2018-08-08 | OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200061A true CR20200061A (es) | 2020-05-23 |
Family
ID=63209389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200061A CR20200061A (es) | 2017-08-08 | 2018-08-08 | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl) |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11597772B2 (es) |
| EP (1) | EP3665196B1 (es) |
| JP (2) | JP7418322B2 (es) |
| KR (1) | KR20200035441A (es) |
| CN (1) | CN111032692A (es) |
| AU (1) | AU2018314765A1 (es) |
| CA (1) | CA3071618A1 (es) |
| CR (1) | CR20200061A (es) |
| ES (1) | ES2933256T3 (es) |
| IL (1) | IL272418B2 (es) |
| MA (1) | MA49830A (es) |
| MX (1) | MX2020001493A (es) |
| MY (1) | MY202382A (es) |
| NZ (1) | NZ761111A (es) |
| PE (1) | PE20200738A1 (es) |
| PL (1) | PL3665196T3 (es) |
| SG (1) | SG11202000985XA (es) |
| TW (2) | TWI772488B (es) |
| UA (1) | UA126204C2 (es) |
| WO (1) | WO2019030260A1 (es) |
| ZA (1) | ZA202000680B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2933256T3 (es) | 2017-08-08 | 2023-02-03 | Hoffmann La Roche | Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG |
| EP3873942A4 (en) * | 2018-10-29 | 2022-12-28 | Tigatx, Inc. | COMPOSITIONS AND METHODS WITH IGA ANTIBODY CONSTRUCTS |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3752017T2 (de) | 1986-03-20 | 1997-08-28 | Nippon Electric Co | Mikrorechner mit Zugriffsfähigkeit auf einen internen Speicher mit gewünschter variabler Zugriffszeit |
| ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
| ES2190087T3 (es) | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
| LT2348051T (lt) | 2003-11-05 | 2019-02-25 | Roche Glycart Ag | Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija |
| GB0718684D0 (en) * | 2007-09-24 | 2007-10-31 | Roche Products Ltd | Treatment method |
| US20130195843A1 (en) * | 2010-06-23 | 2013-08-01 | British Columbia Cancer Agency Branch | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof |
| KR102357699B1 (ko) * | 2013-11-06 | 2022-02-04 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법 |
| DE102013222576A1 (de) | 2013-11-06 | 2015-05-07 | BSH Bosch und Siemens Hausgeräte GmbH | Haushaltsgerät |
| JP6478989B2 (ja) | 2013-11-07 | 2019-03-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法 |
| MA39776A (fr) * | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
| MX2017003121A (es) * | 2014-09-15 | 2017-08-02 | Genentech Inc | Formulaciones de anticuerpos. |
| PT3262071T (pt) * | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
| AU2016276158B2 (en) * | 2015-06-08 | 2022-06-30 | Debiopharm International, S.A. | Anti-CD37 immunoconjugate and anti-CD20 antibody combinations |
| KR20180012873A (ko) | 2015-06-24 | 2018-02-06 | 에프. 호프만-라 로슈 아게 | 림프종 또는 백혈병에서 림프구증가증의 유도에 사용하기 위한 인간 csf-1r에 대한 항체 |
| IL313608A (en) * | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| EP3178848A1 (en) * | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| ES2933256T3 (es) | 2017-08-08 | 2023-02-03 | Hoffmann La Roche | Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG |
-
2018
- 2018-08-08 ES ES18755421T patent/ES2933256T3/es active Active
- 2018-08-08 AU AU2018314765A patent/AU2018314765A1/en active Pending
- 2018-08-08 CN CN201880051243.4A patent/CN111032692A/zh active Pending
- 2018-08-08 MX MX2020001493A patent/MX2020001493A/es unknown
- 2018-08-08 TW TW107127631A patent/TWI772488B/zh active
- 2018-08-08 IL IL272418A patent/IL272418B2/en unknown
- 2018-08-08 EP EP18755421.7A patent/EP3665196B1/en active Active
- 2018-08-08 TW TW111133199A patent/TW202323297A/zh unknown
- 2018-08-08 JP JP2020505912A patent/JP7418322B2/ja active Active
- 2018-08-08 KR KR1020207006102A patent/KR20200035441A/ko not_active Application Discontinuation
- 2018-08-08 NZ NZ761111A patent/NZ761111A/en unknown
- 2018-08-08 WO PCT/EP2018/071462 patent/WO2019030260A1/en unknown
- 2018-08-08 UA UAA202001356A patent/UA126204C2/uk unknown
- 2018-08-08 SG SG11202000985XA patent/SG11202000985XA/en unknown
- 2018-08-08 CA CA3071618A patent/CA3071618A1/en active Pending
- 2018-08-08 PL PL18755421.7T patent/PL3665196T3/pl unknown
- 2018-08-08 CR CR20200061A patent/CR20200061A/es unknown
- 2018-08-08 MA MA049830A patent/MA49830A/fr unknown
- 2018-08-08 PE PE2020000199A patent/PE20200738A1/es unknown
- 2018-08-08 MY MYPI2020000328A patent/MY202382A/en unknown
-
2020
- 2020-01-31 ZA ZA2020/00680A patent/ZA202000680B/en unknown
- 2020-02-06 US US16/784,021 patent/US11597772B2/en active Active
-
2023
- 2023-02-02 US US18/163,810 patent/US20230348611A1/en active Pending
- 2023-08-24 JP JP2023136335A patent/JP2023179425A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019030260A1 (en) | 2019-02-14 |
| US11597772B2 (en) | 2023-03-07 |
| IL272418B1 (en) | 2024-05-01 |
| IL272418B2 (en) | 2024-09-01 |
| MA49830A (fr) | 2021-03-31 |
| MX2020001493A (es) | 2020-03-24 |
| SG11202000985XA (en) | 2020-02-27 |
| CN111032692A (zh) | 2020-04-17 |
| AU2018314765A1 (en) | 2020-01-30 |
| UA126204C2 (uk) | 2022-08-31 |
| NZ761111A (en) | 2024-05-31 |
| TWI772488B (zh) | 2022-08-01 |
| JP2020530002A (ja) | 2020-10-15 |
| PE20200738A1 (es) | 2020-07-23 |
| KR20200035441A (ko) | 2020-04-03 |
| EP3665196A1 (en) | 2020-06-17 |
| ZA202000680B (en) | 2024-09-25 |
| TW202323297A (zh) | 2023-06-16 |
| ES2933256T3 (es) | 2023-02-03 |
| PL3665196T3 (pl) | 2023-01-23 |
| US20200317800A1 (en) | 2020-10-08 |
| CA3071618A1 (en) | 2019-02-14 |
| IL272418A (en) | 2020-03-31 |
| EP3665196B1 (en) | 2022-10-19 |
| MY202382A (en) | 2024-04-24 |
| JP2023179425A (ja) | 2023-12-19 |
| US20230348611A1 (en) | 2023-11-02 |
| TW201910353A (zh) | 2019-03-16 |
| JP7418322B2 (ja) | 2024-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
| NZ751197A (en) | Compounds and methods of treating infections | |
| AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BR112015014458A8 (pt) | compostos derivados de manose, seus intermediários, composição, uso e processos de preparação | |
| MX2018000590A (es) | Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79). | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
| MX2015012528A (es) | Inhibidores macrociclicos de cinasa inducibles por sal. | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| BR112016030730A8 (pt) | composto | |
| EA201591773A1 (ru) | Макроциклические ингибиторы rip2-киназы | |
| ZA201805358B (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| ZA202000680B (en) | Obinutuzumab treatment of a dlbcl patient subgroup | |
| ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
| EA201790609A1 (ru) | Макроциклические ингибиторы rip2-киназы | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. |